The DOI matches its Crossref record.
The Economic Burden of Schizophrenia in the United States in 2002
Abstract
OBJECTIVE: This study quantifies excess annual costs associated with schizophrenia patients in the United States in 2002 from a societal perspective. METHOD: Annual direct medical costs associated with schizophrenia were estimated separately for privately (N = 1090) and publicly (Medicaid; N = 14,074) insured patients based on administrative claims data, including a large private claims database and the California Medicaid program (MediCal) database, and compared separately to demographically/geographically matched control samples (1 case:3 controls). Medicare costs of patients over age 65 years were imputed using the Medicare/MediCal dual-eligible patients (N = 1491) and published statistics. Excess annual direct non-health care costs were estimated for law enforcement, homeless shelters, and research/training related to schizophrenia. Excess annual indirect costs were estimated for 4 components of productivity loss: unemployment, reduced workplace productivity, premature mortality from suicide, and family caregiving using a human capital approach based on market wages. All costs were adjusted to 2002 dollars using the Medical Care Consumer Price Index and were based on the reported prevalence in the National Comorbidity Survey Replication. RESULTS: The overall U.S. 2002 cost of schizophrenia was estimated to be $62.7 billion, with $22.7 billion excess direct health care cost ($7.0 billion outpatient, $5.0 billion drugs, $2.8 billion inpatient, $8.0 billion long-term care). The total direct non-health care excess costs, including living cost offsets, were estimated to be $7.6 billion. The total indirect excess costs were estimated to be $32.4 billion. CONCLUSION: Schizophrenia is a debilitating illness resulting in significant costs. The indirect excess cost due to unemployment is the largest component of overall schizophrenia excess annual costs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Genetic architectures of psychiatric disorders: the emerging picture and its implications
Sullivan, P. F., Daly, M. J., & O'Donovan, M. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3240 · Cited by 1,177
Garland, E. L., Fredrickson, B., Kring, A. M., Johnson, D. P., Meyer, P. S., & Penn, D. L. (2010) · Clinical Psychology Review · doi:10.1016/j.cpr.2010.03.002 · Cited by 1,035
“Schizophrenia is among the most devastating of all mental illnesses, resulting in societal costs of approximately 62 billion dollars, making it among the costliest mental or physical illness in the United States (Wu et al., 2005).”
Schizophrenia, “just the facts” 4. Clinical features and conceptualization
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.03.005 · Cited by 1,027
The Burden of Schizophrenia on Caregivers: A Review
Awad, A. G., & Voruganti, L. N. P. (2008) · PharmacoEconomics · doi:10.2165/00019053-200826020-00005 · Cited by 809
Global economic burden of schizophrenia: a systematic review
Chaiyakunapruk, N., Chong, H. Y., Teoh, S. L., Wu, D. B.-C., Kotirum, S., & Chiou, C.-F. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s96649 · Cited by 643
Dendritic spine pathology in schizophrenia
Glausier, J. R., & Lewis, D. A. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2012.04.044 · Cited by 581
Hashimoto, T., Arion, D., Unger, T., Maldonado-Avilés, J. G., Morris, H. M., Volk, D. W., Mirnics, K., & Lewis, D. A. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002011 · Cited by 490
The economic and social burden of compulsive hoarding
Tolin, D. F., Frost, R. O., Steketee, G., Gray, K. D., & Fitch, K. E. (2008) · Psychiatry Research · doi:10.1016/j.psychres.2007.08.008 · Cited by 445
Psychosocial Treatments for Schizophrenia
Mueser, K. T., Deavers, F., Penn, D. L., & Cassisi, J. E. (2013) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050212-185620 · Cited by 402
The social and economic burden of treatment-resistant schizophrenia: a systematic literature review
Kennedy, J. L., Altar, C. A., Taylor, D. L., Degtiar, I., & Hornberger, J. C. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32836508e6 · Cited by 392
Estimating the Economic Burden of Racial Health Inequalities in the United States
LaVeist, T. A., Gaskin, D., & Richard, P. (2011) · International Journal of Health Services · doi:10.2190/hs.41.2.c · Cited by 378
Grant, P. M. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.129 · Cited by 353
DiBonaventura, M., Gabriel, S., Dupclay, L., Gupta, S., & Kim, E. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-20 · Cited by 333
Sahakian, B., & Morein-Zamir, S. (2007) · Nature · doi:10.1038/4501157a · Cited by 326
Ben-Zeev, D., Kaiser, S. M., Brenner, C. J., Begale, M., Duffecy, J., & Mohr, D. C. (2013) · Psychiatric Rehabilitation Journal · doi:10.1037/prj0000019 · Cited by 304
The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal
Brissos, S., Veguilla, M. R., Taylor, D., & Balanzá-Martinez, V. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314540297 · Cited by 297
Killackey, E., Jackson, H. J., & McGorry, P. D. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.043109 · Cited by 293
Quality of life in caregivers of patients with schizophrenia: A literature review
Caqueo-Urízar, A., Gutiérrez-Maldonado, J., & Miranda-Castillo, C. (2009) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-7-84 · Cited by 261
Dendritic spines: Revisiting the physiological role
Chidambaram, S. B., Rathipriya, A. G., Bolla, S. R., Bhat, A., Ray, B., Mahalakshmi, A. M., Manivasagam, T., Thenmozhi, A. J., Essa, M. M., Guillemin, G. J., et al. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.01.005 · Cited by 255
Paliperidone for schizophrenia
Dolder, C., Nelson, M., & Deyo, Z. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070261 · Cited by 254
Prediction of Functional Outcome in Individuals at Clinical High Risk for Psychosis
Carrión, R. E., McLaughlin, D., Goldberg, T. E., Auther, A. M., Olsen, R. H., Olvet, D. M., Correll, C. U., & Cornblatt, B. A. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.1909 · Cited by 250
Tabarés-Seisdedos, R., & Rubenstein, J. L. R. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.2 · Cited by 244
The economic burden of bipolar I disorder in the United States in 2015
Cloutier, M., Greene, M., Guerin, A., Touya, M., & Wu, E. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.09.011 · Cited by 215
Self-citationSchizophrenia--Time to Commit to Policy Change
Fleischhacker, W. W., Arango, C., Arteel, P., Barnes, T. R. E., Carpenter, W., Duckworth, K., Galderisi, S., Halpern, L., Knapp, M., Marder, S. R., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu006 · Cited by 214
Making the Case for IPS Supported Employment
Bond, G. R., & Drake, R. E. (2014) · Administration and Policy in Mental Health and Mental Health Services Research · doi:10.1007/s10488-012-0444-6 · Cited by 189
Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications
Coyle, J. T., Basu, A., Benneyworth, M., Balu, D., & Konopaske, G. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-25758-2_10 · Cited by 180
“Keywords Schizophrenia; NMDA receptors; Glutamate; GABA; Ketamine; D-Serine; Dopamine hypothesis; D-Amino acid oxidase; Neuregulin; Dysbindin 1 Introduction Schizophrenia affects approximately 1% of the population and is the seventh most costly medical disorder to Society (Wu et al. 2005).”
BackgroundZuccoli, G. S., Saia-Cereda, V. M., Nascimento, J. M., & Martins-de-Souza, D. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00493 · Cited by 157
“…2017 | Volume 11 | Article 493 patients in both productive and social aspects of life, resulting in low level of education, work absenteeism, unemployment, social isolation, marital disruption, and the need for caregiving in many cases (Kessler et al., 1997, 1998; Wu et al., 2005; Hyman, 2008).”
BackgroundAmann, L. C., Gandal, M. J., Lin, R., Liang, Y., & Siegel, S. J. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0152-4 · Cited by 99
“economic burden of schizophrenia to be $63 billion, a cost that is disproportionately large compared to diseases of similar prevalence ( 2 ,3).”
BackgroundInfluentialAntipsychotic maintenance treatment: time to rethink
Moncrieff, J. (2015) · PLoS Medicine · doi:10.1371/journal.pmed.1001861 · Cited by 80
The efficacy of supported employment for middle-aged and older people with schizophrenia
Twamley, E. W., Vella, L., Burton, C. Z., Becker, D. R., Bell, M. D., & Jeste, D. V. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2011.11.036 · Cited by 75
Eisner, E., Drake, R. J., Berry, N., Barrowclough, C., Emsley, R., Machin, M., & Bucci, S. (2019) · JMIR mHealth and uHealth · doi:10.2196/11568 · Cited by 73
Citrome, L., Ota, A., Nagamizu, K., Perry, P., Weiller, E., & Baker, R. A. (2016) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000123 · Cited by 74
Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis
Medic, G., Higashi, Littlewood, K., Diez, Granström, O., & Kahn (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s39303 · Cited by 63
Offord, S., Wong, B., Mirski, D., Baker, R. A., & Lin, J. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2012.751025 · Cited by 62
Kotzeva, A., Mittal, D., Desai, S., Judge, D., & Samanta, K. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2022.2157596 · Cited by 57
Cognition in at-risk mental states for psychosis
de Paula, A. L. D., Hallak, J. E. C., Maia-de-Oliveira, J. P., Bressan, R. A., & Machado-de-Sousa, J. P. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.09.006 · Cited by 43
Gaudiano, B., Davis, C., Epstein-Lubow, G., Johnson, J., Mueser, K., & Miller, I. (2017) · Healthcare · doi:10.3390/healthcare5020023 · Cited by 22
Morrison, S. C., & Cohen, A. S. (2014) · Cognitive Neuropsychiatry · doi:10.1080/13546805.2014.931839 · Cited by 21
Metadata
- Authors
- Wu, E. Q., Birnbaum, H. G., Shi, L., Ball, D. E., Kessler, R. C., Moulis, M., & Aggarwal, J.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2005-09-15
- Volume
- 66
- Issue
- 09
- Pages
- 1122-1129
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2916950229
- Cited by
- 614
- References
- 0
- FWCI
- 11.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.